Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Claire L. S. Kelly"'
Autor:
Kristopher K. Frese, Donna M. Graham, Nicholas Hickson, Alexandra Clipson, Crispin J. Miller, Sumitra Mohan, Saba Ferdous, Matthew G Krebs, Alexander J Vickers, Bedirhan Kilerci, Helen Eaton, Caroline Dive, Siobhan Southam, Roopa Kurup, Hannah Frost, Ciara O’Brien, Fiona C Thistlethwaite, Richard Marais, Allan M. Jordan, Mahmood Ayub, Robert Metcalf, Jaseela Chiramel, Louise Carter, Daniel J. White, Emma Dean, Matthew Howell, Sreeja Aruketty, Avinash Gupta, Joanne Dransfield, Ged Brady, Kamrun Nessa, Donal Landers, Claire L. S. Kelly, Shaun Villa, Julie Stevenson, Dominic G. Rothwell, Nigel K Smith, Andrew Hughes, Nadina Tinsley, Natalie Cook, Sakshi Gulati, Andrew L. Wallace
Publikováno v:
Rothwell, D, Ayub, M, Cook, N, Thistlethwaite, F, Carter, L, Dean, E, Smith, N, Villa, S, Dransfield, J, Clipson, A, White, D, Nessa, K, Ferdous, S, Howell, M, Gupta, A, Kilerci, B, Mohan, S, Frese, K, Gulati, S, Miller, C, Jordan, A, Eaton, H, Hickson, N, O'Brien, C, Graham, D, Kelly, C, Aruketty, S, Metcalf, R, Chiramel, J, Tinsley, N, Vickers, AJ, Kurup, R, Frost, H, Stevenson, J, Southam, S, Landers, D, Wallace, A, Marais, R, Hughes, AM, Brady, G, Dive, C & Krebs, M 2019, ' Utility of ctDNA to support patient selection for early phase clinical trials: The TARGET Study ', Nature Medicine, vol. 25, no. 5, pp. 738-743 . https://doi.org/10.1038/s41591-019-0380-z, https://doi.org/10.1038/s41591-019-0380-z
Next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) supports blood-based genomic profiling but is not yet routinely implemented in the setting of a phase I trials clinic. TARGET is a molecular profiling program with the primary aim to m
Autor:
Claire L. S. Kelly, Stefan Symeonides, Udai Banerji, Gavin Bennett, T.R. Jeffry Evans, Sawretse Leslie, Natalie Cook, Marc Pittman, Patricia Roxburgh, Sidath Katugampola, Narmatha Sabaratnam, Lisa Godfrey, Irene Moreno Candilejo, Neil Tremayne, Rashmi Passi, Gillian Langford, Maria Koehler
Publikováno v:
Banerji, U, Cook, N, Evans, T R J, Moreno Candilejo, I, Roxburgh, P, Kelly, C L S, Sabaratnam, N, Passi, R, Leslie, S, Katugampola, S, Godfrey, L, Tremayne, N, Bennett, G, Koehler, M, Langford, G, Symeonides, S N & Pittman, M 2018, ' A Cancer Research UK phase I/IIa trial of BT1718 (a first in class Bicycle Drug Conjugate) given intravenously in patients with advanced solid tumours. ', pp. TPS2610-TPS2610 . https://doi.org/10.1200/jco.2018.36.15_suppl.tps2610
TPS2610Background: Membrane type I matrix metalloproteinase (MT1-MMP) is a member of the matrix metalloproteinase (MMP) family which are involved in tissue remodelling through proteolysis of extrac...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec57a8e2054b1369fb396cd3d1421088
https://doi.org/10.1200/jco.2018.36.15_suppl.tps2610
https://doi.org/10.1200/jco.2018.36.15_suppl.tps2610
Autor:
Alexander J Vickers, Sreeja Aruketty, Fiona H Blackhall, Claire L. S. Kelly, Roopa Kurup, Fiona C Thistlethwaite, Seamus O'Reilly, Donna M. Graham, Louise Carter, Natalie Cook, M Norfolk, Thomas E. Jordan, Andrew Walsh, Raffaele Califano, Matthew G Krebs, Yvonne Summers, C Thomson, Anne White, Andrew Smith, Paul Taylor, Nadina Tinsley, Dilshad Chang
Publikováno v:
Journal of Thoracic Oncology. 13:S470
Publikováno v:
Journal of Clinical Oncology. 31:224-224
224 Background: The TROPIC Trial demonstrated improved overall survival in patients with mCRPC who progressed during or after treatment with docetaxel. The trial established cabazitaxel as a tolerable and viable second line treatment option in these